WASHINGTON, April 29 -- Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a release from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) on Wednesday.
The conclusion came out of preliminary data analysis from a randomized, controlled trial involving 1,063 patients, which began on Feb. 21.
Preliminary results indicated that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo, according to the release.
Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo.
The results also suggested a survival benefit, with a mortality rate of 8 percent for the group receiving remdesivir versus 11.6 percent for the placebo group.
An independent data and safety monitoring board overseeing the trial met on April 27 to review the data and shared their interim analysis with the study team.
Based upon their review of the data, the board members noted that remdesivir was better than placebo from the perspective of primary endpoint, or patients' time to recovery. It is a metric often used in influenza trials.
The first participant in the trial was an American who was repatriated after being quarantined on the Diamond Princess cruise ship that docked in Yokohama, Japan.
The patient volunteered to participate in the study at the first study site, the University of Nebraska Medical Center, in February 2020, according to the NIAID.
A total of 68 sites ultimately joined the study, 47 in the United States and 21 in countries in Europe and Asia.
The trial, sponsored by the NIAID, part of the National Institutes of Health, is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19.
Remdesivir, developed by American biopharmaceutical company Gilead Sciences, is an investigational broad-spectrum antiviral treatment administered via daily infusion for 10 days. It is not yet licensed or approved anywhere globally while multiple Phase 3 studies are ongoing to determine the safety and efficacy of the drug for the treatment of COVID-19.
Gilead also announced preliminary results of phase 3 trial of remdesivir in patients with severe COVID-19, showing more than half of patients in both 5-day and 10-day treatment groups were discharged from the hospital after two weeks.
The trial evaluated 5-day and 10-day dosing durations of remdesivir in hospitalized patients with severe COVID-19. The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course, according to Gilead Sciences.
"At Day 14, 64.5 percent of patients in the 5-day treatment group and 53.8 percent of patients in the 10-day treatment group achieved clinical recovery," the company said in a statement.
No new safety signals were identified with remdesivir across either treatment group.
"Multiple concurrent studies are helping inform whether remdesivir is a safe and effective treatment for COVID-19 and how to best utilize the drug," said Merdad Parsey, chief medical officer of Gilead Sciences.
"While additional data are still needed, these results help to bring a clearer understanding of how treatment with remdesivir may be optimized, if proven safe and effective," said Aruna Subramanian, clinical professor of medicine at Stanford University School of Medicine, and one of the lead investigators of the study.
Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19.
These randomized, open-label, multicenter studies began enrolling patients in March 2020 and will enroll a total of approximately 1,000 patients in the initial phase of the studies, in countries with high prevalence of COVID-19, according to Gilead.
Anthony Fauci, director of the NIAID, said Wednesday he was told data from the trial showed a "clear cut positive effect in diminishing time to recover."
Remdesivir has shown some promise in treating SARS and MERS, which are also caused by coronaviruses. As there is currently no cure for treating COVID-19, health authorities around the world have pinned hopes on drugs such as remdesivir to reduce the duration of COVID-19 in patients.
怎么洗粉扑最干净,老外教你一招!
爱情中的“备胎”:英语怎么说?
美文赏析:想成为精英,生活就得有规律
国内英语资讯:Taiwan officials remarks on independence dangerous: mainland spokesperson
Manchester United: Song sheets and 'cheerleader' ideas discussed by club 曼联主场太安静?俱乐部考虑活跃现场的方案
心理学家才知道的一些秘密
国内英语资讯:China imposes tariff on 128 items of U.S. imports
幸福的情侣会在周末做这些事情
小测验 — 描述少儿读物种类的英语词汇
国内英语资讯:China approves 3 new IPO applications
The problem with disposable coffee 外带咖啡纸杯的“回收难题”
美国通胀升至近一年最高水平
国外最新研究:多去演唱会还能延长寿命!
考验情商的时刻:怎么跟老板谈请假和辞职?专家给你支了几招……
这个创意有点暖:为保护独居女性,日本公司发明窗帘上的男友
习近平:打好决胜全面建成小康社会三大攻坚战
新西兰试行每周四天工作 结果效率奇高
好贴心!自动贩卖机根据心情发放“精神小食”
国内英语资讯:Interview: City of London to facilitate smart future of Chinas planned new metropolis
网球到底是黄色还是绿色?看看费德勒怎么说
雄安的拼音到底是Xiongan还是Xiong’an,你分得清楚吗?
数据泄露到底有多厉害?信用卡最严重!
国内英语资讯:Bullet trains smooth traffic to Xiongan
别人家的公司!英国公司让员工自定薪水 涨薪需获同事认可
调查:读研更容易让人抑郁
5月1日起增值税税率降低 全年减税将超4000亿
写下过去的失败有助于帮你减轻压力
“梁静茹取关张韶涵”上热搜!如何用英语表达“取关”?
BBC推荐四月佳片:这4部电影最精彩
国内英语资讯:China, Mekong River countries cooperate for brighter future: MRC official
不限 |
英语教案 |
英语课件 |
英语试题 |
不限 |
不限 |
上册 |
下册 |
不限 |